Jaguar Health (JAGX) Granted Orphan Drug Designation for Crofelemer by European Medicines

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Jaguar Health (NASDAQ: JAGX) and Napo Therapeutics, the Italian corporation established by Jaguar Health in Italy in 2021 that focuses on development and commercialization of crofelemer in orphan and rare diseases, thus expanding access to crofelemer to patients in Europe, today announced that the European Commission has adopted the decision to grant…

Source link

Portable Charger Market to Bring Revolution in the Industry During 2022-27 | Microsoft Corporation, SONY EUROPE B.V.

Billionaire Mo Ibrahim attacks ‘hypocrisy’ over Africa’s gas | Gas

RelatedPosts

Empowering Africa’s Pharmaceutical Future: The Critical Role Of Local API Manufacturing

Middle East Active Pharmaceutical Ingredients Market to Reach

Pharma Tech names new CEO to expand geographic reach

Yourgene Health Cystic Fibrosis Base assay receives IVDR accreditation

Latest Post

$48.2 Billion by 2035 — How Cloud-Based Networking Is Simplifying Enterprise IT Operations

$148.6 Billion by 2035 — How Cloud Data Warehousing Is Revolutionizing Business Intelligence

$30.5 Billion by 2035 — How Technology Is Revolutionizing Real Estate Transactions and Management

$65.4 Billion by 2035 — How Cloud-Native WAF Is Protecting Modern Web Applications

$45 Billion by 2035 — How Cloud-Connected Robots Are Powering the Automation Revolution

Categories

Recent News

$48.2 Billion by 2035 — How Cloud-Based Networking Is Simplifying Enterprise IT Operations

$148.6 Billion by 2035 — How Cloud Data Warehousing Is Revolutionizing Business Intelligence

$30.5 Billion by 2035 — How Technology Is Revolutionizing Real Estate Transactions and Management

$65.4 Billion by 2035 — How Cloud-Native WAF Is Protecting Modern Web Applications

Browse by Category-